Power3 Medical Products, Inc. (OTCBB: PWRM.OB) strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies. The Company will be guided in all of its dealings with its customers, partners, shareholders, associates and investors by the philosophy of best practices.
PWRM’s study of protein concentrations in blood serum has resulted in a remarkable breakthrough in the diagnosis of Neurodegenerative diseases, including Alzheimer’s, ALS (Lou Gerig’s Disease), and Parkinson’s.
BC-SeraPro™ is a blood serum test designed to diagnose breast cancer in individuals. The test is based on proteomic technology in which a blood serum sample drawn from a patient will monitor the concentration of each protein biomarker residing in a panel of blood serum protein biomarkers to determine if a patient has breast cancer.
Amgen Inc. (Nasdaq: AMGN) recently announced that the European Commission (EC) has granted marketing authorization for Prolia(R) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. Prolia has been approved in all 27 European Union member states plus Norway, Iceland and Liechtenstein. The European approval of Prolia marks the first approval of the product worldwide.
PGNX
Genzyme Corp. (NASDAQ: GENZ) announced that its Board of Directors has voted to pursue several actions to increase shareholder value. The company will initiate a $2 billion stock buyback, under which $1 billion of stock will be repurchased in the near term and financed with debt. The additional $1 billion of stock will be repurchased during the next 12 months.
The company also plans to pursue strategic alternatives for its Genetic testing, Diagnostic products and Pharmaceutical intermediates businesses. Options could include divestiture, spin-out, or management buy-out.
Gilead Sciences, Inc. (Nasdaq:GILD) recently reported that its corporate presentation will be webcast from the Sanford C. Bernstein 26th Annual Strategic Decisions Conference in New York.
John C. Martin, PhD, Gilead’s Chairman and Chief Executive Officer, will provide an overview of the company on Thursday, June 3 at 2:00 p.m. Eastern Daylight Time.
To access the live webcast via the internet log on to www.gilead.com. Please connect to the company’s website at least 15 minutes prior to the live presentation to ensure adequate time for any software download that may be necessary to listen to the webcast.
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) recently announced the presentation of preclinical data on novel monoclonal antibodies against toxins produced by the bacterium Clostridium difficile (C. difficile). The monoclonal antibodies effectively neutralized the cell-killing activities of the toxins in vitro and significantly improved survival in a stringent animal model of C. difficile infection. C. difficile is the leading cause of hospital-acquired diarrhea in the United States and represents a growing global public health challenge. The monoclonal antibodies were identified as part of the Company’s ongoing drug discovery efforts in infectious diseases. The data were presented today at the 110th General Meeting of the American Society for Microbiology in San Diego.
C. difficile-associated disease typically occurs when an individual is exposed to this pathogen while taking antibiotics, since a course of antibiotic treatment can disrupt the normal intestinal bacteria and provide an opportunity for infection in the colon. The C. difficile bacteria produce two toxins, A and B, that can damage cells that line the colon, and can result in mild-to-severe diarrhea and, in some cases, potentially life-threatening inflammation of the colon.
******************************************************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreet publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreet.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)
